David DeLucia's most recent trade in Kyntra Bio Inc. was a trade of 60 Common Stock done at an average price of $6.8 . Disclosure was reported to the exchange on March 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kyntra Bio Inc | David DeLucia | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.83 per share. | 06 Mar 2026 | 60 | 4,429 (0%) | 0% | 6.8 | 410 | Common Stock |
| Kyntra Bio Inc | David DeLucia | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Kyntra Bio Inc | David DeLucia | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.42 per share. | 06 Dec 2025 | 52 | 4,489 (0%) | 0% | 8.4 | 438 | Common Stock |
| Kyntra Bio Inc | David DeLucia | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.09 per share. | 06 Jun 2025 | 53 | 4,541 (0%) | 0% | 12.1 | 641 | Common Stock |
| Kyntra Bio Inc | David DeLucia | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.82 per share. | 06 Jun 2025 | 51 | 4,594 (0%) | 0% | 7.8 | 399 | Common Stock |
| Kyntra Bio Inc | David DeLucia | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 06 Mar 2025 | 2,325 | 116,137 (0%) | 0% | 0.4 | 907 | Common Stock |